IP Library Granted Patent US 11,786,521
Granted Patent B2
US 11,786,521 · App. 17/503,760 · Granted Oct 17, 2023

Methods of treating neurofibromatosis with perillyl alcohol

Inventor: Thomas Chen (La Canada, CA)
Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
A61K31/495A61K9/0043A61K31/045A61K31/366A61K31/4015A61K31/415A61K31/4188A61K31/635A61K45/06A61K47/54A61K47/542A61K47/543A61K47/55A61N5/10C07B59/00C07C33/14C07D207/26C07D231/12C07D487/04C07B2200/05C07C2601/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,786,521
App. No.
17/503,760
Granted
Oct 17, 2023
Kind
B2
Abstract

The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

Claims (12)

1. A method of inhibiting or decreasing Ras level and/or activity in a cell, comprising administering to the cell perillyl alcohol, an iso-perillyl alcohol, or a combination thereof,

further comprising administering temozolomide, dimethyl celecoxib, or rolipram.

2. A method of inhibiting or decreasing Ras level and/or activity in a subject, comprising administering to the subject an effective amount of perillyl alcohol, an iso-perillyl alcohol, or a combination thereof,

further comprising administering temozolomide, dimethyl celecoxib, or rolipram.

3. The method of claim 1 , further comprising administering a statin selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and rosuvastatin.

4. The method of claim 1 , further comprising administering prostratin.

5. The method of claim 2 , wherein said administration is by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

6. The method of claim 2 , further comprising administering a statin selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and rosuvastatin.

7. The method of claim 2 , further comprising administering prostratin.

8. A method of inhibiting or decreasing Ras level and/or activity in a cell or in a subject, comprising administering to the cell perillyl alcohol, an iso-perillyl alcohol, or a combination thereof,

further comprising administering a compound selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin, rosuvastatin and prostratin.

9. The method of claim 6 , wherein said administration is by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: NEONC TECHNOLOGIES INC.
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 063726/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2021
From: CHEN, THOMAS
To: NEONC TECHNOLOGIES, INC.
Reel/Frame 057841/0573 →
Continuity (7)
Continuation 16313388
Continuation In Part 15291847 · Oct 12, 2016
Continuation 13818972
Provisional Application 62357545 · Jul 1, 2016
Provisional Application 61471402 · Apr 4, 2011
Provisional Application 61377747 · Aug 27, 2010
Related Publication 20220054481A1 · Feb 24, 2022